What is the Future of B Cell Engagers in Cancer Therapy?
The future of B Cell Engagers in cancer therapy looks promising, with ongoing research aimed at improving their efficacy and safety. Combination therapies that pair B Cell Engagers with other immunotherapies, such as checkpoint inhibitors, are being explored to overcome resistance and enhance anti-tumor responses. Advances in protein engineering are also expected to yield next-generation BiTEs with improved pharmacokinetics and reduced toxicity. Furthermore, expanding the range of targetable antigens could enable the application of B Cell Engagers to a broader spectrum of cancers, including solid tumors.
